The resumption of injections of the Johnson & Johnson vaccine in the United States does not seem more than a formality.
Experts from the American health authority indeed recommended Friday the resumption of vaccination with Johnson & Johnson's serum on the other side of the Atlantic, suspended since April 13 after rare cases of thrombosis.
Read alsoFour vaccines tested
The vaccine "is recommended" for the adult population, concludes this Friday a group assembled at the request of the American Centers for Disease Control and Prevention (CDC), the main American public health agency.
The CDC Director will make the final decision.
A benefit / risk balance deemed positive
Health authorities had announced a pause in the use of the vaccine developed by the American laboratory to investigate several cases of women who developed severe cases of blood clots in association with low levels of platelets after their injection.
On April 13, the Janssen laboratory announced a slowdown in its shipments to Europe after the suspension decided in the United States. The American authorities then launched an investigation to shed light on a case of death and that of a person in critical condition after receiving a dose of the vaccine. The US Medicines Agency (FDA) said earlier in a statement that it was "investigating six reported cases in the United States of people who developed severe cases of blood clots after receiving the vaccine." . But according to experts, as was decided for example in Europe with the AstraZeneca vaccine, the risk / benefit balance is clearly in favor of a recovery.